- Home
- ARHS vs PCRX Comparison
ARHS vs PCRX Comparison
Compare ARHS & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARHS | PCRX |
|---|---|---|
| Founded | 1986 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 956.8M | 1.0B |
| IPO Year | 2021 | 2010 |
Fundamental Metrics
Financial Performance| Metric | ARHS | PCRX |
|---|---|---|
| Price | $9.68 | $36.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 9 |
| Target Price | $10.69 | ★ $33.00 |
| AVG Volume (30 Days) | 1.5M | ★ 1.6M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.59% | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | ★ 0.30 | 0.19 |
| Revenue | ★ $1,379,222,000.00 | $541,533,000.00 |
| Revenue This Year | $5.91 | $3.84 |
| Revenue Next Year | $6.48 | $4.73 |
| P/E Ratio | ★ $32.50 | $191.37 |
| Revenue Growth | 8.51 | ★ 26.04 |
| 52 Week Low | $5.57 | $18.80 |
| 52 Week High | $12.08 | $36.46 |
Technical Indicators
Market Signals| Indicator | ARHS | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.36 | 84.48 |
| Support Level | $9.60 | $21.78 |
| Resistance Level | $10.45 | N/A |
| Average True Range (ATR) | 0.38 | 0.69 |
| MACD | 0.05 | 1.14 |
| Stochastic Oscillator | 55.56 | 98.86 |
Price Performance
Historical ComparisonAbout ARHS Arhaus Inc.
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.